Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables discovery of highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body.

The USA-based company focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. As of 2023, Kymera has utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology.